Reference
1. Li C, Schneider JM, Schneider EM. Disulfiram Inhibits Opsonin-Independent Phagocytosis and Migration of Human long-lived in Vitro Cultured Phagocytes from Multiple Inflammatory Diseases. Cells. 2024 Mar 18;13(6):535. doi: 10.3390/calls13060635. PMID: 38534379: PMCID: PMC10968875
2. Prof. Dr. med. Marion Schneider, Hyperthermia induced ER(endoplasmic reticulum) stress with and without supplementation by vitamin C, Clinic of Neurology, Ulm University Hospital, Oberer Eselsberg 45, 89081 Ulm, Esther Havemann, Christian Scheiber, M. Sc, Session 4: Aktuelle Forschung und praktische Anwendung, 05 Oct., DGHT2024
3. Dr. rer. Hum. Claudia Vollbracht, Studien Update: hochdosierte intravenöses Vitamin C in der Onkologie und bei Long COVID, Session5: Aus Industrie und Forschung: Hyperthermie im Mosaik komplementärer Therapieoption, 05 Oct., DGHT2024
4. Carr, A.C. and J. Cook, Intravenous Vitamin C for Cancer Therapy -Identifying the Current Gaps in Our Knowledge.
5. Mayland, C.R., M.l. Bennett, and K. Allan, Vitamin C deficiency in cancer patients. Palliat Med, 2005. 19(1): p. 17-20.
6. Campbell, E.J., et al., Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels. BMC Cancer, 2019. 19(1): p. 307.
7. Gandhi, M., et al.. Scurvy: Rediscovering a Forgotten Disease. Diseases, 2023. 11(2).
8 Blaszczak, W., et al., Vitamin C as a Modulator of the Response to Cancer Therapy. Molecules, 2019. 24(3).
9. Carr, A.C., M.C. Vissers, and J.S.Cook, The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life. Front Oncol, 2014. 4: p. 283.
10. Ou, j., et al., A randomized phase trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer. J Adv Res, 2020. 24: p. 175-182.
11. Ou, J., et al., A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer. Integr Cancer Ther, 2020. 19: p. 1534735419895591.
12. Rodríguez, D.M., et al., Total lymphocyte count in cancer patients with lymphopenia treated with intravenous vitamin C: Results of an observational study. Translational Medicine Communications, 2017. 2(1): p. 3.
13. Zhao, H., et al., The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk Res, 2018. 66: p. 1-7.
14. Ma Y., et al., High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med, 2014. 6(222): p. 222ra18.
15. Wang, F. et al., A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study). Clin Cancer Res, 2022. 28(19): p. 4232-4239.
16. Zaher, A., et al., Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy. Front Immunol, 2022. 13: p. 989000.
17. Bedhiafi, T., et al., The potential role of vitamin C in empowering cancer immunotherapy. Biomed Pharmacother, 2022 146: p. 112553.
본 칼럼은 의학전문 매거진 엠디포스트에서 매주 연재중입니다.